Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells

Beyond a well‐recognized effect of KRAS mutations in determining de novo inefficacy of cetuximab (CTX) in metastatic colorectal cancer, we urgently need a biomarker signature for predicting CTX efficacy in KRAS wild‐type (WT) tumors. CTX‐adapted EGFR gene‐amplified KRAS WT tumor cell populations wer...

Ausführliche Beschreibung